Italia markets open in 2 hours 26 minutes

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,2550-0,0150 (-1,18%)
Alla chiusura: 04:00PM EDT
1,2700 +0,01 (+1,20%)
Dopo ore: 04:49PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,2700
Aperto1,2800
Denaro0,0000 x 3200
Lettera0,0000 x 1000
Min-Max giorno1,1750 - 1,2981
Intervallo di 52 settimane1,1600 - 4,6800
Volume176.950
Media Volume148.418
Capitalizzazione31,935M
Beta (5 anni mensile)1,21
Rapporto PE (ttm)N/D
EPS (ttm)-0,5700
Prossima data utili28 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A5,00
  • GlobeNewswire

    iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023

    Company is exploring strategic options for its Therapy business lineNASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023. Based on preliminary, unaudited financial information,

  • GlobeNewswire

    iCAD Announces Leadership Transition

    Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as President and CEO. Stacey will remain with the Company through April 30, 2023

  • GlobeNewswire

    New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy

    Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023NASHUA, N.H., March 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts radiologists’ efficiency and accuracy. The